These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 36056476)

  • 1. Sodium-glucose cotransporter-2 inhibitors and the risk of gout in patients with type 2 diabetes mellitus: A propensity-score-matched, new-user design study with an active comparator using the IQVIA Medical Research Data UK database.
    Subramanian A; Gokhale K; Sainsbury C; Nirantharakumar K; Toulis KA
    Diabetes Obes Metab; 2023 Jan; 25(1):156-165. PubMed ID: 36056476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Sodium-Glucose Transport Protein 2 Inhibitor Use for Type 2 Diabetes and Incidence of Gout in Taiwan.
    Chung MC; Hung PH; Hsiao PJ; Wu LY; Chang CH; Wu MJ; Shieh JJ; Chung CJ
    JAMA Netw Open; 2021 Nov; 4(11):e2135353. PubMed ID: 34797368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effects of sulphonylureas, dipeptidyl peptidase-4 inhibitors and sodium-glucose co-transporter-2 inhibitors added to metformin monotherapy: a propensity-score matched cohort study in UK primary care.
    Wilkinson S; Williamson E; Pokrajac A; Fogarty D; Stirnadel-Farrant H; Smeeth L; Douglas IJ; Tomlinson LA
    Diabetes Obes Metab; 2020 May; 22(5):847-856. PubMed ID: 31957254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The associations of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as add-on to metformin with fracture risk in patients with type 2 diabetes mellitus.
    van Hulten V; Driessen JHM; Starup-Linde JK; Al-Mashhadi ZK; Viggers R; Klungel OH; Souverein PC; Vestergaard P; Stehouwer CDA; van den Bergh JP
    Diabetes Obes Metab; 2023 Nov; 25(11):3235-3247. PubMed ID: 37503747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Below-Knee Amputation: A Multicenter Observational Study.
    Yu OHY; Dell'Aniello S; Shah BR; Brunetti VC; Daigle JM; Fralick M; Douros A; Hu N; Alessi-Severini S; Fisher A; Bugden SC; Ronksley PE; Filion KB; Ernst P; Lix LM;
    Diabetes Care; 2020 Oct; 43(10):2444-2452. PubMed ID: 32759360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and safety of sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: A nationwide population-based study.
    Han SJ; Ha KH; Lee N; Kim DJ
    Diabetes Obes Metab; 2021 Mar; 23(3):682-691. PubMed ID: 33236515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significant reduction in chronic kidney disease progression with sodium-glucose cotransporter-2 inhibitors compared to dipeptidyl peptidase-4 inhibitors in adults with type 2 diabetes in a UK clinical setting: An observational outcomes study based on international guidelines for kidney disease.
    Idris I; Zhang R; Mamza JB; Ford M; Morris T; Banerjee A; Khunti K
    Diabetes Obes Metab; 2022 Nov; 24(11):2138-2147. PubMed ID: 35676798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SGLT2 Inhibitors and the Risk of Acute Kidney Injury in Older Adults With Type 2 Diabetes.
    Zhuo M; Paik JM; Wexler DJ; Bonventre JV; Kim SC; Patorno E
    Am J Kidney Dis; 2022 Jun; 79(6):858-867.e1. PubMed ID: 34762974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium-glucose cotransporter-2 inhibitors and the risk of urinary tract infection among diabetic patients in Japan: Target trial emulation using a nationwide administrative claims database.
    Takeuchi Y; Kumamaru H; Hagiwara Y; Matsui H; Yasunaga H; Miyata H; Matsuyama Y
    Diabetes Obes Metab; 2021 Jun; 23(6):1379-1388. PubMed ID: 33606891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Safety of Sodium-Glucose Cotransporter 2 Inhibitors Versus Dipeptidyl Peptidase 4 Inhibitors and Sulfonylureas on the Risk of Diabetic Ketoacidosis.
    Dawwas GK; Flory JH; Hennessy S; Leonard CE; Lewis JD
    Diabetes Care; 2022 Apr; 45(4):919-927. PubMed ID: 35147696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular outcomes of sodium glucose cotransporter-2 inhibitors in patients with type 2 diabetes.
    Dawwas GK; Smith SM; Park H
    Diabetes Obes Metab; 2019 Jan; 21(1):28-36. PubMed ID: 30039524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sodium-glucose co-transporter-2 inhibitors and the risk of ketoacidosis in patients with type 2 diabetes mellitus: A nationwide population-based cohort study.
    Kim YG; Jeon JY; Han SJ; Kim DJ; Lee KW; Kim HJ
    Diabetes Obes Metab; 2018 Aug; 20(8):1852-1858. PubMed ID: 29569427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: Scandinavian register based cohort study.
    Pasternak B; Ueda P; Eliasson B; Svensson AM; Franzén S; Gudbjörnsdottir S; Hveem K; Jonasson C; Wintzell V; Melbye M; Svanström H
    BMJ; 2019 Aug; 366():l4772. PubMed ID: 31467044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of hyperkalaemia in patients with type 2 diabetes mellitus prescribed with SGLT2 versus DPP-4 inhibitors.
    Wu MZ; Teng TK; Tsang CT; Chan YH; Lee CH; Ren QW; Huang JY; Cheang IF; Tse YK; Li XL; Xu X; Tse HF; Lam CSP; Yiu KH
    Eur Heart J Cardiovasc Pharmacother; 2024 Jan; 10(1):45-52. PubMed ID: 37942588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study.
    Filion KB; Lix LM; Yu OH; Dell'Aniello S; Douros A; Shah BR; St-Jean A; Fisher A; Tremblay E; Bugden SC; Alessi-Severini S; Ronksley PE; Hu N; Dormuth CR; Ernst P; Suissa S;
    BMJ; 2020 Sep; 370():m3342. PubMed ID: 32967856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of sepsis and pneumonia in patients initiated on SGLT2 inhibitors and DPP-4 inhibitors.
    Wu MZ; Chandramouli C; Wong PF; Chan YH; Li HL; Yu SY; Tse YK; Ren QW; Yu SY; Tse HF; Lam CSP; Yiu KH
    Diabetes Metab; 2022 Nov; 48(6):101367. PubMed ID: 35753654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sodium-glucose cotransporter-2 inhibitors and the risk of gout: A Danish population based cohort study and symmetry analysis.
    Lund LC; Højlund M; Henriksen DP; Hallas J; Kristensen KB
    Pharmacoepidemiol Drug Saf; 2021 Oct; 30(10):1391-1395. PubMed ID: 33881179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium-Glucose Cotransporter-2 Inhibitors and Urinary Tract Infections: A Propensity Score-matched Population-based Cohort Study.
    Alkabbani W; Zongo A; Minhas-Sandhu JK; Eurich DT; Shah BR; Alsabbagh MW; Gamble JM
    Can J Diabetes; 2022 Jun; 46(4):392-403.e13. PubMed ID: 35513988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sodium-Glucose Cotransporter 2 Inhibitors and the Short-term Risk of Bladder Cancer: An International Multisite Cohort Study.
    Abrahami D; Tesfaye H; Yin H; Vine S; Hicks B; Yu OHY; Campeau L; Platt RW; Schneeweiss S; Patorno E; Azoulay L
    Diabetes Care; 2022 Dec; 45(12):2907-2917. PubMed ID: 36170656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fracture Risk of Sodium-Glucose Cotransporter-2 Inhibitors in Chronic Kidney Disease.
    Cowan A; Jeyakumar N; Kang Y; Dixon SN; Garg AX; Naylor K; Weir MA; Clemens KK
    Clin J Am Soc Nephrol; 2022 Jun; 17(6):835-842. PubMed ID: 35618342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.